Chief Strategy Officer, Cell and Gene Therapy Catapult
Nick Johnson is the Chief Strategy and Impact Officer at the Cell and Gene Therapy Catapult (CGTC), part of the UK Government’s extensive network of organisations that provide Innovation services and solutions to support market and industry growth. CGTC is at the forefront of helping to build a vibrant Advanced Therapy Medicinal Products (ATMP) market in the UK. Uniquely engaging across academia, industry and government to support the discovery, development and manufacture of effective treatments for rare and complex diseases.
Prior to this Nick was the Commercial Director at CPI, part of the High Value Manufacturing Catapult (HVMC), where his responsibilities included business development, strategic marketing, marketing communications, grant proposals and reporting of impact to government and other stakeholder groups. Earlier in his career he has held senior strategic and commercial roles at Catalent, Johnson Matthey, Sigma Aldrich and Dr Reddy’s.
He holds a first-class bachelors of science degree from the University of Manchester and a PhD in organic chemistry from the same institution. His master of business administration was gained at Imperial College and he is also a Fellow of the Royal Society of Chemistry.